This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2005 by Zeneus Pharma.
Recruitment status was:  Recruiting
Information provided by:
Zeneus Pharma Identifier:
First received: November 7, 2005
Last updated: NA
Last verified: November 2005
History: No changes posted
To study the pharmacokinetic profile of the therapeutic schedule in order to demonstrate absence of negative interactions among the 3 drugs administered

Condition Intervention Phase
Metastatic Breast Cancer Drug: Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I-II Study of Liposomal Doxorubicin (Myocet®), Docetaxel and Trastuzumab as First-Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer

Resource links provided by NLM:

Further study details as provided by Zeneus Pharma:

Estimated Enrollment: 45
Study Start Date: December 2003
Detailed Description:
  1. To assess the maximum tolerated dose (MTD) of Myocet at different dosages in combination with Taxotere at the fixed dose of 35 mg/m2 on day 2 and 9 every 21 days and weekly Herceptin as first line therapy in patients affected by HER-2/neu positive metastatic breast cancer
  2. To enhance the proportion of complete remission
  3. To allow the feasibility of the combination of Herceptin with both Myocet and Taxotere without an enhanced risk of cardiotoxicity

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HER-2/neu overexpression assessed by FISH test or with immunohistochemical methods: Dako(the result must be 3+ with dakotest); if the immunohistochemical test results 2+ it is needed a positive FISH test
  • Female < 70yrs
  • Histologically or cytologically proven breast cancer.
  • Metastatic or locally advanced breast cancer (clinical stage: III-IV)
  • Adequate hematological, hepatic, renal and cardiac function, the latter confirmed by echocardiography with FEVS ≥50%
  • Prior adjuvant chemotherapy if doxorubicin total dose ≤300 mg/m2, epirubicin total dose ≤450 mg/m2

Exclusion Criteria:

  • History of cardiopathy
  • Severe hepatic and renal diseases
  • Brain metastases as the only parameter of disease
  • Contraindication to the use of corticosteroids as premedication
  • Acute infectious diseases
  • Insulin-dependent diabetes
  • History of other cancers except for adequately treated basal cell skin cancer or in situ carcinoma of the cervix
  • Concurrent treatment with any other cancer therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00250874

Contact: Professor Amadori +39 0543 731737
Contact: Professor Gasparini

Ospedale Pietrantoni Recruiting
Forli, Italy
Principal Investigator: Professor Amadori         
Sponsors and Collaborators
Zeneus Pharma
Principal Investigator: Professor Amadori Ospedale Pietrantoni, Forli, Italy
Principal Investigator: Professor Gasparini San Filippo Neri, Rome, Italy
  More Information Identifier: NCT00250874     History of Changes
Other Study ID Numbers: Myocet 008 (L017)
Study First Received: November 7, 2005
Last Updated: November 7, 2005

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Liposomal doxorubicin
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors processed this record on August 16, 2017